• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

野生型 SARS-CoV-2 主蛋白酶酰基酶中间产物与生理 C 末端自加工位点的晶体结构。

Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site.

机构信息

Department of Biochemistry and Molecular Biology and Centre for Blood Research, The University of British Columbia, Vancouver, BC, Canada.

Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.

出版信息

Nat Commun. 2020 Nov 18;11(1):5877. doi: 10.1038/s41467-020-19662-4.

DOI:10.1038/s41467-020-19662-4
PMID:33208735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7674412/
Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the pathogen that causes the disease COVID-19, produces replicase polyproteins 1a and 1ab that contain, respectively, 11 or 16 nonstructural proteins (nsp). Nsp5 is the main protease (M) responsible for cleavage at eleven positions along these polyproteins, including at its own N- and C-terminal boundaries, representing essential processing events for subsequent viral assembly and maturation. We have determined X-ray crystallographic structures of this cysteine protease in its wild-type free active site state at 1.8 Å resolution, in its acyl-enzyme intermediate state with the native C-terminal autocleavage sequence at 1.95 Å resolution and in its product bound state at 2.0 Å resolution by employing an active site mutation (C145A). We characterize the stereochemical features of the acyl-enzyme intermediate including critical hydrogen bonding distances underlying catalysis in the Cys/His dyad and oxyanion hole. We also identify a highly ordered water molecule in a position compatible for a role as the deacylating nucleophile in the catalytic mechanism and characterize the binding groove conformational changes and dimerization interface that occur upon formation of the acyl-enzyme. Collectively, these crystallographic snapshots provide valuable mechanistic and structural insights for future antiviral therapeutic development including revised molecular docking strategies based on M inhibition.

摘要

严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2)是导致 COVID-19 疾病的病原体,它产生复制酶多聚蛋白 1a 和 1ab,分别包含 11 或 16 种非结构蛋白 (nsp)。Nsp5 是主要蛋白酶 (M),负责在这些多聚蛋白的 11 个位置进行切割,包括其自身的 N 端和 C 端边界,这是后续病毒组装和成熟的关键加工事件。我们通过在活性位点突变 (C145A) 的情况下,以 1.8Å 的分辨率确定了该半胱氨酸蛋白酶在其野生型自由活性位点状态、具有天然 C 端自切割序列的酰基-酶中间状态和与产物结合状态下的 X 射线晶体结构。我们描述了酰基-酶中间物的立体化学特征,包括在 Cys/His 二联体和氧阴离子穴中催化的关键氢键距离。我们还在一个位置上鉴定出一个高度有序的水分子,该位置适合作为催化机制中的脱酰基亲核试剂,并描述了在形成酰基-酶时发生的结合槽构象变化和二聚化界面。总的来说,这些晶体学快照为未来的抗病毒治疗开发提供了有价值的机制和结构见解,包括基于 M 抑制的修订分子对接策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/5003c34ff136/41467_2020_19662_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/1745a50a34b7/41467_2020_19662_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/dc0b6664c576/41467_2020_19662_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/9a4d0b34c025/41467_2020_19662_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/8a1955ee2d9b/41467_2020_19662_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/01c98ffabb20/41467_2020_19662_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/5003c34ff136/41467_2020_19662_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/1745a50a34b7/41467_2020_19662_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/dc0b6664c576/41467_2020_19662_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/9a4d0b34c025/41467_2020_19662_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/8a1955ee2d9b/41467_2020_19662_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/01c98ffabb20/41467_2020_19662_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e0a/7674412/5003c34ff136/41467_2020_19662_Fig6_HTML.jpg

相似文献

1
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site.野生型 SARS-CoV-2 主蛋白酶酰基酶中间产物与生理 C 末端自加工位点的晶体结构。
Nat Commun. 2020 Nov 18;11(1):5877. doi: 10.1038/s41467-020-19662-4.
2
X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation.SARS-CoV-2 主要蛋白酶多蛋白切割位点的 X 射线晶体学表征,这些切割位点对于病毒的加工和成熟至关重要。
Nat Commun. 2022 Sep 3;13(1):5196. doi: 10.1038/s41467-022-32854-4.
3
Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.靶向冠状病毒主蛋白酶的二聚化:一种有潜力的广谱治疗策略。
ACS Comb Sci. 2020 Jun 8;22(6):297-305. doi: 10.1021/acscombsci.0c00058. Epub 2020 May 27.
4
Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.鉴定 SARS-CoV-2 主蛋白酶的高亲和力抑制剂:迈向有效的 COVID-19 治疗。
Virus Res. 2020 Oct 15;288:198102. doi: 10.1016/j.virusres.2020.198102. Epub 2020 Jul 24.
5
Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.基于与病毒蛋白酶分子相互作用的抗 SARS-CoV 药物的设计与评估。
Molecules. 2020 Aug 27;25(17):3920. doi: 10.3390/molecules25173920.
6
Structural plasticity of SARS-CoV-2 3CL M active site cavity revealed by room temperature X-ray crystallography.室温 X 射线晶体学揭示 SARS-CoV-2 3CL M 活性位点腔的结构可塑性。
Nat Commun. 2020 Jun 24;11(1):3202. doi: 10.1038/s41467-020-16954-7.
7
Room-temperature neutron and X-ray data collection of 3CL M from SARS-CoV-2.来自严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的3CL M的室温中子和X射线数据收集。
Acta Crystallogr F Struct Biol Commun. 2020 Oct 1;76(Pt 10):483-487. doi: 10.1107/S2053230X20011814. Epub 2020 Sep 15.
8
Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.计算真菌代谢产物 Pyranonigrin A 作为一种新型 SARS-CoV-2 病毒主要蛋白酶(M)抑制剂的潜力,该病毒是使用对接和分子动力学模拟发现的。
Biophys Chem. 2020 Sep;264:106425. doi: 10.1016/j.bpc.2020.106425. Epub 2020 Jul 6.
9
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.新型 SARS-CoV-2 病毒主要蛋白酶的批准蛋白酶抑制剂的有效性的计算机评估。
Molecules. 2020 May 29;25(11):2529. doi: 10.3390/molecules25112529.
10
Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M enzyme through in silico approach.通过计算机模拟方法揭示抗 SARS-CoV-2 M 酶的具有抗病毒作用的植物化学成分
Life Sci. 2020 Aug 15;255:117831. doi: 10.1016/j.lfs.2020.117831. Epub 2020 May 22.

引用本文的文献

1
Small-angle X-ray scattering profile calculation for high-resolution models of biomacromolecules.生物大分子高分辨率模型的小角X射线散射轮廓计算
J Appl Crystallogr. 2025 Jul 16;58(Pt 4):1332-1346. doi: 10.1107/S160057672500562X. eCollection 2025 Aug 1.
2
Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding.二聚体严重急性呼吸综合征冠状病毒3C样蛋白酶(SARS-CoV-2 Mpro)的抑制表现出正协同性以及共价和非共价结合的混合情况。
iScience. 2025 May 28;28(7):112773. doi: 10.1016/j.isci.2025.112773. eCollection 2025 Jul 18.
3
SARS-CoV-2 Mpro Dihedral Angles Reveal Allosteric Signaling.

本文引用的文献

1
Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 M by QM/MM computational methods.通过量子力学/分子力学计算方法揭示新冠病毒M蛋白的蛋白水解分子机制。
Chem Sci. 2020 Jun 25;11(39):10626-10630. doi: 10.1039/d0sc02823a.
2
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.SARS-CoV-2 主蛋白酶的晶体学和亲电片段筛选。
Nat Commun. 2020 Oct 7;11(1):5047. doi: 10.1038/s41467-020-18709-w.
3
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.猫冠状病毒药物可抑制新型冠状病毒的主要蛋白酶并阻断病毒复制。
严重急性呼吸综合征冠状病毒2型主蛋白酶的二面角揭示变构信号传导。
Proteins. 2025 Jul;93(7):1281-1289. doi: 10.1002/prot.26814. Epub 2025 Mar 3.
4
Evaluating the structure-based virtual screening performance of SARS-CoV-2 main protease: A benchmarking approach and a multistage screening example against the wild-type and Omicron variants.评估严重急性呼吸综合征冠状病毒2型主要蛋白酶基于结构的虚拟筛选性能:一种基准测试方法以及针对野生型和奥密克戎变体的多阶段筛选示例
PLoS One. 2025 Feb 19;20(2):e0318712. doi: 10.1371/journal.pone.0318712. eCollection 2025.
5
Distal protein-protein interactions contribute to nirmatrelvir resistance.远端蛋白质-蛋白质相互作用导致对奈玛特韦耐药。
Nat Commun. 2025 Feb 1;16(1):1266. doi: 10.1038/s41467-025-56651-x.
6
Recognition and cleavage of human tRNA methyltransferase TRMT1 by the SARS-CoV-2 main protease.新型冠状病毒2型主要蛋白酶对人tRNA甲基转移酶TRMT1的识别与切割
Elife. 2025 Jan 7;12:RP91168. doi: 10.7554/eLife.91168.
7
Catalytic Mechanism of SARS-CoV-2 3-Chymotrypsin-Like Protease as Determined by Steady-State and Pre-Steady-State Kinetics.通过稳态和预稳态动力学确定的新型冠状病毒3-胰凝乳蛋白酶样蛋白酶的催化机制
ACS Catal. 2024 Nov 27;14(24):18292-18309. doi: 10.1021/acscatal.4c04695. eCollection 2024 Dec 20.
8
Revealing SARS-CoV-2 M mutation cold and hot spots: Dynamic residue network analysis meets machine learning.揭示新冠病毒M突变的冷热点:动态残基网络分析与机器学习相结合
Comput Struct Biotechnol J. 2024 Oct 22;23:3800-3816. doi: 10.1016/j.csbj.2024.10.031. eCollection 2024 Dec.
9
Allostery in homodimeric SARS-CoV-2 main protease.同源二聚体 SARS-CoV-2 主蛋白酶的变构作用。
Commun Biol. 2024 Nov 4;7(1):1435. doi: 10.1038/s42003-024-07138-w.
10
Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation.作为严重急性呼吸综合征冠状病毒2主要蛋白酶抑制剂的不对称咪唑-4,5-二甲酰胺衍生物:设计、合成及生物学评价
RSC Med Chem. 2024 Sep 3;15(11):3880-8. doi: 10.1039/d4md00414k.
Nat Commun. 2020 Aug 27;11(1):4282. doi: 10.1038/s41467-020-18096-2.
4
Structural plasticity of SARS-CoV-2 3CL M active site cavity revealed by room temperature X-ray crystallography.室温 X 射线晶体学揭示 SARS-CoV-2 3CL M 活性位点腔的结构可塑性。
Nat Commun. 2020 Jun 24;11(1):3202. doi: 10.1038/s41467-020-16954-7.
5
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease.博赛匹韦、GC-376 和钙蛋白酶抑制剂 II、XII 通过靶向病毒主蛋白酶抑制 SARS-CoV-2 病毒复制。
Cell Res. 2020 Aug;30(8):678-692. doi: 10.1038/s41422-020-0356-z. Epub 2020 Jun 15.
6
Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.靶向冠状病毒主蛋白酶的二聚化:一种有潜力的广谱治疗策略。
ACS Comb Sci. 2020 Jun 8;22(6):297-305. doi: 10.1021/acscombsci.0c00058. Epub 2020 May 27.
7
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur.新型冠状病毒主蛋白酶抑制剂卡莫氟的结构基础
Nat Struct Mol Biol. 2020 Jun;27(6):529-532. doi: 10.1038/s41594-020-0440-6. Epub 2020 May 7.
8
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.基于结构的针对 SARS-CoV-2 主蛋白酶的抗病毒药物候选物的设计。
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
9
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
10
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.